|Bid||129.00 x 100|
|Ask||129.20 x 100|
|Day's Range||129.10 - 133.18|
|52 Week Range||71.46 - 137.26|
|PE Ratio (TTM)||180.24|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vertex stock toppled alongside the biotech sector Friday, but an analyst upgraded shares on the likelihood Vertex will succeed against competitors in cystic fibrosis.
The Nasdaq is on course for a strong weekly gain and is leading the key indexes Friday. Vertex has led the biotech group higher in recent weeks.
Needham upgraded shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) from Hold to Buy, with a price target of $155. The price target, according to the firm, is based on 25 times its estimated ...